IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery
Patients whose blood turned positive for tumour DNA after cystectomy lived longer with atezolizumab than placebo; patients who stayed ctDNA-negative did well without any treatment. It is the first ctDNA-guided adjuvant trial to improve survival.
IMvigor011 enrolled patients with muscle-invasive bladder cancer after radical cystectomy into ctDNA surveillance with a tumour-informed assay (Signatera). Those who became ctDNA-positive within a year were randomised 2:1 to atezolizumab or placebo; those who remained negative were followed without treatment.
In the ctDNA-positive randomised population, atezolizumab improved disease-free survival (HR 0.64) and overall survival (HR 0.59) versus placebo. Patients who never became ctDNA-positive had very low recurrence rates, supporting the safety of withholding adjuvant therapy from them. The design was built on the exploratory IMvigor010 ctDNA analysis (Powles, Nature 2021), which had shown benefit confined to ctDNA-positive patients.
Regulatory approval in 2026 made this the first indication defined by a ctDNA result.
- Disease-free survival in ctDNA-positive patients: HR 0.64 for atezolizumab vs placebo
- Overall survival: HR 0.59, a rare survival gain in the adjuvant setting
- Patients who remained ctDNA-negative on surveillance had excellent outcomes without treatment
- Roughly two-thirds of surveilled patients avoided adjuvant immunotherapy altogether
After bladder removal, a blood test can now tell who needs immunotherapy and who can safely be spared it. This is the model for MRD-guided adjuvant therapy across cancers: treat the blood-positive, watch the blood-negative.
- Applies to a tumour-informed assay with defined sampling schedule; other assays and intervals are not interchangeable
- Placebo rather than standard adjuvant nivolumab (CheckMate 274) as comparator, so it does not settle which drug or strategy is best
- Some ctDNA-negative patients still relapsed; surveillance intervals and duration remain to be optimised
- Cost and logistics of serial testing over 12 months are substantial
Pages like this
not linked directly; found by shared links- IdeaFormally qualify tumour-DNA blood tests as a surrogate endpoint for adjuvant trials
Shares ctDNA MRD → adjuvant therapy decision, IMvigor011, Signatera, Circulating tumour DNA (ctDNA).
- IdeaA national residual-disease weather service: serial blood tests for every curatively treated patient, pooled
Shares IMvigor011, Signatera, Circulating tumour DNA (ctDNA), Dormant cells and minimal residual disease.
- IdeactDNA-triggered escalation in early TNBC
Shares ctDNA MRD → adjuvant therapy decision, IMvigor011, Signatera, Dormant cells and minimal residual disease.
- Key paperDYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer
Shares ctDNA MRD → adjuvant therapy decision, Neoadjuvant / adjuvant / perioperative, Circulating tumour DNA (ctDNA), Dormant cells and minimal residual disease.
- IdeaUse a blood test at six weeks to decide whether to keep going
Shares Molecular-progression switching beyond ESR1, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Trial design, endpoints and cost.
- IdeaTake the blood test, and give the drug, at the right time of day
Shares Circulating tumour DNA (ctDNA), Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Biomarkers are not validated or standardised.
- Key paperGALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold
Shares Signatera, Circulating tumour DNA (ctDNA), Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD).
- IdeactDNA-guided adjuvant therapy in stage II-III melanoma
Shares IMvigor011, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.